Skip to main
JNJ
JNJ logo

JNJ Stock Forecast & Price Target

JNJ Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 27%
Buy 20%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Johnson & Johnson's Innovative Medicine segment achieved revenues of $15.20 billion in the second quarter of 2025, surpassing expectations and reflecting a robust growth trajectory, especially in oncology, immunology, and neurology. The company raised its full-year 2025 sales guidance by approximately $2.4 billion to a range of $93.2 to $93.6 billion, benefiting from both operational strengths and favorable currency fluctuations. With management expressing confidence in stronger operational sales growth in the second half of 2025 and into 2026, there is a positive outlook for continued financial performance, contributing to recent stock price gains.

Bears say

The financial outlook for Johnson & Johnson is overshadowed by declining revenues in critical segments, with Orthopedics sales of $2.31 billion showing a year-over-year operational decline of 1.6%, compounded by competitive pressures in the U.S. MedTech market and inventory dynamics. The pharmaceutical division is also facing a substantial risk of reduced organic revenue growth, highlighted by potential contributions falling below $57 billion by 2025 due to loss of exclusivity for key drugs and the need to effectively navigate an evolving product pipeline. Additionally, ongoing litigation costs and challenges in M&A integration pose further threats to the company's financial stability and predictability, raising concerns about future growth prospects.

JNJ has been analyzed by 15 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 20% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Johnson & Johnson (JNJ) Forecast

Analysts have given JNJ a Buy based on their latest research and market trends.

According to 15 analysts, JNJ has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $196.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $196.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Johnson & Johnson (JNJ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.